Theravance Biopharma (TBPH) Operating Income: 2013-2025
Historic Operating Income for Theravance Biopharma (TBPH) over the last 13 years, with Sep 2025 value amounting to -$6.5 million.
- Theravance Biopharma's Operating Income rose 40.44% to -$6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.8 million, marking a year-over-year increase of 25.40%. This contributed to the annual value of -$46.9 million for FY2024, which is 16.21% up from last year.
- Per Theravance Biopharma's latest filing, its Operating Income stood at -$6.5 million for Q3 2025, which was down 136.88% from -$2.7 million recorded in Q2 2025.
- In the past 5 years, Theravance Biopharma's Operating Income ranged from a high of -$2.7 million in Q2 2025 and a low of -$83.9 million during Q1 2021.
- In the last 3 years, Theravance Biopharma's Operating Income had a median value of -$10.8 million in 2024 and averaged -$11.5 million.
- In the last 5 years, Theravance Biopharma's Operating Income spiked by 82.95% in 2022 and then slumped by 47.44% in 2024.
- Quarterly analysis of 5 years shows Theravance Biopharma's Operating Income stood at -$56.2 million in 2021, then skyrocketed by 68.96% to -$17.4 million in 2022, then soared by 64.20% to -$6.2 million in 2023, then crashed by 47.44% to -$9.2 million in 2024, then soared by 40.44% to -$6.5 million in 2025.
- Its last three reported values are -$6.5 million in Q3 2025, -$2.7 million for Q2 2025, and -$14.4 million during Q1 2025.